相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Timo Rath et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2015)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Towards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institution
S. Vyas et al.
HAEMOPHILIA (2014)
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A
Manuel D. Carcao et al.
BLOOD (2013)
Molecular approaches for improved clotting factors for hemophilia
Randal J. Kaufman et al.
BLOOD (2013)
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
I. A. Ivens et al.
HAEMOPHILIA (2013)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients
R. Ljung et al.
HAEMOPHILIA (2013)
Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy
S. Bjorkman
HAEMOPHILIA (2013)
Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA
A. Tiede et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Evidence of clinically significant extravascular stores of factor IX
D. Feng et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
Hubert J. Metzner et al.
THROMBOSIS AND HAEMOSTASIS (2013)
The hope and reality of long-acting hemophilia products
Steven W. Pipe
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
Sven Bjorkman et al.
BLOOD (2012)
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
Amy D. Shapiro et al.
BLOOD (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
Elena Santagostino et al.
BLOOD (2012)
Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States
N. Duncan et al.
HAEMOPHILIA (2012)
Association Between Physical Activity and Risk of Bleeding in Children With Hemophilia
Carolyn R. Broderick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX
P. W. Collins et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier et al.
BLOOD (2011)
Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China
R. Wu et al.
HAEMOPHILIA (2011)
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
I. E. M. Den Uijl et al.
HAEMOPHILIA (2011)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Baisong Mei et al.
BLOOD (2010)
Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients
Kathelijn Fischer et al.
PLOS ONE (2009)
A survey of adherence to haemophilia therapy in six European countries: results and recommendations
P. De Moerloose et al.
HAEMOPHILIA (2008)
Extending half-life in coagulation factors: where do we stand?
David Lillicrap
THROMBOSIS RESEARCH (2008)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients
Jonathan K. Armstrong et al.
CANCER (2007)
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
NJ Ganson et al.
ARTHRITIS RESEARCH & THERAPY (2006)
A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres
VS Blanchette et al.
HAEMOPHILIA (2003)
The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia
K Fischer et al.
BLOOD (2002)
Catheter-related deep venous thrombosis in children with hemophilia
JM Journeycake et al.
BLOOD (2001)
Barriers to compliance with prophylaxis therapy in haemophilia
MR Hacker et al.
HAEMOPHILIA (2001)
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia
HM van den Berg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
